A5013493537- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Calcium signaling and nucleotide metabolism
- Cutaneous lymphoproliferative disorders research
- Retinoids in leukemia and cellular processes
- Chemokine receptors and signaling
- Oral Health Pathology and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- CAR-T cell therapy research
- Fungal Infections and Studies
- Oral health in cancer treatment
- Salivary Gland Disorders and Functions
- Epigenetics and DNA Methylation
- Advanced biosensing and bioanalysis techniques
- Angiogenesis and VEGF in Cancer
- Occupational and environmental lung diseases
- Neutropenia and Cancer Infections
Medical University of Lodz
2016-2025
Copernicus Memorial Hospital
2003-2025
Centrum Onkologii
2019
Wroclaw Medical University
2015
Patients with primary refractory AML and early relapses have unfavorable prognoses require innovative therapeutic approaches. Purine analogs fludarabine (FA) cladribine (2-CdA) increase cytotoxic effect of Ara-C in leukemic blasts inhibit DNA repair mechanisms; therefore its association mitoxantrone (MIT) results a synergistic effect. In the current report, we present final multi-center phase II study evaluating efficacy toxicity CLAG-M salvage regimen poor risk refractory/relapsed...
The aim of the study was to determine levels selected cytokines and chemokines in serum multiple myeloma (MM) patients treated with bortezomib-based regimens. A total 71 MM were examined: 41 primary refractory disease (17) or early relapse (28), 30 who bortezomib sensitive no progression for at least six months. Patients demonstrated CR PR after therapies longer than months treatment discontinuation designated sensitive. Serum cytokine assayed Bio-Rad Bio-Plex Pro Human Cytokine 27-Plex...
Abstract Intensive induction chemotherapy using anthracycline and cytarabine backbone is considered the most effective upfront therapy in physically fit older patients with acute myeloid leukemia (AML). However, outcomes of standard elderly AML are inferior to those observed younger patients, they still unsatisfactory. As addition cladribine known improve outcome patients. The present randomized phase II study compares efficacy toxicity DAC (daunorubicin plus cladribine) regimen DA...
Given the recent findings on importance of CD38 signaling in pathogenesis B-cell chronic lymphocytic leukemia (B-CLL), we hypothesized that single nucleotide polymorphisms (SNP) gene may be related to B-CLL risk. We evaluated two potentially functional SNPs, intronic rs6449182 (184C>G) and missense rs1800561 (418C>T, Arg140Trp) hospital-based case-control studies (study A validation study B). Genotyping was done using PCR-based assays a total 460 Polish Caucasian patients with 503...
The 17p13.1 deletion that causes loss of the p53-encoding TP53 gene is most powerful predictor a poor response to conventional therapy and shortened survival in patients with chronic lymphocytic leukemia (CLL). results this study have demonstrated cladribine cyclophosphamide regimen may improve treatment poor-risk patient population.In study, authors retrospectively analyzed efficacy toxicity 2-CdA combination (the CC regimen) 20 previously untreated B-cell CLL who had reported Polish Adult...
The acquisition of new aberrations during the course chronic lymphocytic leukemia (CLL) named clonal evolution (CE) is usually detected by one two methods: chromosome banding analysis (CBA) and interphase fluorescence in situ hybridization (I-FISH). purpose this study was to compare usefulness FISH CBA for detecting CE evaluate its influence on clinical outcome. were performed at time points: baseline follow-up. Thirty-eight previously untreated patients with CLL included study. I-FISH...
Second malignancies are frequent complications in patients with chronic lymphocytic leukemia (CLL). Hodgkin's disease (HD) has been observed approximately 0.5% of the CLL and is known as type Richter's syndrome (H-RS). We present a 64-year-old male patient familial history who developed H-RS abdominal lymph nodes 6 years after diagnosis 18 months treatment cladribine (2-CdA) cyclophosphamide. HD was diagnosed by fine needle aspiration. The refractory to two courses CHOP three ABVD...
Richter syndrome (RS) is a transformation to high-grade non-Hodgkin lymphoma in patients with chronic lymphocytic leukaemia (CLL). RS may develop lymph nodes or rarely extranodally. Skin localization of has been described only few cases. We present 77-year-old woman who developed isolated diffuse large B-cell (LBCL) the skin nose without any other symptoms RS. The LBCL was clonally distinct from original bone marrow CLL cells. Moreover, cells were positive for LMP-1 segment Epstein-Barr...
In this study Jagged-1 and Dll-1 surface expression as well Notch-1 receptor intracellular domain (Notch-1-IC) were assessed by multi-color flow cytometry in leukemic blasts obtained from 88 patients with acute myeloid leukemia (AML). CD34+peripheral blood stem cells (PBSCs) used a control. The median of was significantly higher AML than PBSCs (p=0.001 p=0.002, respectively). Higher Notch-1-IC detected poor-risk karyotype compared to good- intermediate-risk groups (p=0.035). our study,...
Evidence indicates that there are significant alterations in gut microbiota diversity and composition patients with hematological malignancies. The present study investigated the oral intestinal microbiome chronic lymphocytic leukemia (CLL) (n=81) age-matched healthy volunteers (HVs; n=21) using 16S ribosomal RNA next-generation sequencing. Changes both structures were identified, a high abundance of
Monosomal karyotype (MK) and complex (CK) are poor prognostic factors in acute myeloid leukemia (AML). A comprehensive analysis of cytogenetic clinical influencing an outcome AML-CK+ was performed. The impact cladribine containing induction on treatment results also evaluated. We analyzed 125 patients with treated within PALG protocols. MK found 75 (60%) individuals. overall complete remission (CR) rate 66 intensively 62% vs. 28% CK+ MK− MK+ group (p = .01). No difference CR observed between...
Journal Article Primary cutaneous marginal zone B‐cell lymphoma in a patient with chronic lymphocytic leukaemia Get access E. Robak, Robak Departments of Dermatology, Pathology Correspondence: Tadeusz Robak. E‐mail: robaktad@csk.umed.lodz.pl Search for other works by this author on: Oxford Academic Google Scholar D. Jesionek‐Kupnicka, Jesionek‐Kupnicka PathologyCopernicus Memorial Hospital, Ciołkowskiego 2, 93–510 Łodz, Poland T. Copernicus PolandHaematology A. Holub, Holub Wawrzyniak,...
Richter's syndrome (RS) refers to the development of aggressive non-Hodgkin's lymphoma (NHL) during course chronic lymphocytic leukaemia (CCL). It occurs in approximately 3% patients with CLL. The isolated form this complication bone is extremely rare and, so far, has not been described a patient treated cladribine (2-CdA). We report case CLL successfully 2-CdA, where diffuse large B-cell (LBCL) developed 2 years after diagnosis Rai II and one year completion 2-CdA treatment. RS was first...
The SMAD proteins are responsible for transducing signals from activated transforming growth factor-beta. This is the first study assessing expression of SMAD-1/8, SMAD-2/3, SMAD-4, and SMAD-7 in chronic lymphocytic leukemia cells with regard to their clinical significance potential prognostic value. Overexpression SMAD-1/8 was observed 160 patients compared 42 healthy volunteers (p = 0.023) associated a more progressive course disease 0.016). Moreover, high correlated other,...
To improve the efficacy of therapeutic options in chronic lymphocytic leukemia (CLL) an vitro system to determine response mononuclear blood cells from patients was elaborated. The study combines four approaches, i.e., cell viability, apoptosis rate, differential scanning calorimetry (DSC), and immunoblotting develop personalized therapy protocols based on sensitivity drug exposure individual CLL patients. complementary analyses were performed 28 peripheral samples previously untreated...
Thymidine kinase (TK) activity is a marker of biological that allows the indolent and aggressive forms chronic lymphocytic leukemia (CLL) to be distinguished. The aims study were determine relationship between TK clinical status prognosis, as well compare its with other prognostic predictive factors. was measured in patient sera at time diagnosis using DiviTum method, mean value being 439 Du/L. A correlation found risk disease progression (p=0.045). optimal discriminative prediction CLL 600...
AbstractCoexistence of B-cell chronic lymphocytic leukemia (B-CLL) and myelomonocytic (CMML) is an unusal event, to our knowledge, only four such cases have been reported in the literature. We report a 68-year-old white woman whom these two diseases were diagnosed concomitantly. The diagnosis was made on basis peripheral blood count, morphology immunophenotyping, bone marrow cytology histology. Interphase FISH analysis detected 13q14.3 deletion lymphocytes nuclei no abnormality monocytes...